Teva Presents P-IV (UNITE) Study Results of Ajovy (fremanezumab) for Migraine and Major Depressive Disorder at World Congress of Neurology
Shots:
- The P-IV study evaluating fremanezumab in patients with migraine & major depressive disorder, showed that patients experienced a reduction in monthly migraine days (MMD) of –5.1 vs –2.9, reductions in migraine attacks & depressive symptoms
- Patients (33%) achieved ≥50% reduction in over 13% in PBO during the 12wk. double-blind period with a sustained reduction over the longer term, improvements in disability outcomes with a sustained reduction in their disability, mean change at 12wk. using the HIT-6 (-8.8 vs -5.2) and using CGI-S score (-1.1 vs -0.8), respectively
- Ajovy is a humanized mAb that selectively targets the calcitonin gene-related peptide & was approved for the prevention of migraines in adults who have 4 migraine days per month
Ref: Teva | Image: Teva
Related News:- Teva's Ajovy (fremanezumab) Receives NICE Positive Recommendation for Prevention of Migraine in Adults
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
